The in vitro induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to Mycobacterium tuberculosis is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and antiinflammatory cytokines

Journal of Infectious Diseases

Volumn 177, Issue 5, 1998, Pages 1332-1338

  Goletti, Delia ^b   Weissman, Drew ^c   Jackson, Robert W ^c   Collins, Frank ^c   Kinter, Audrey ^c   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLAMMATION; MONONUCLEAR CELL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUBERCULOSIS; VIRUS REPLICATION;

EID: 0031948393     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515276     Document Type: Article

References (25)

1. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6.
2. De Cock KM, Binkin NJ, Zuber PL, Tappero JW, Castro KG. Research issues involving HIV-associated tuberculosis in resource-poor countries. JAMA 1996;276:1502-7.
3. Centers for Diseases Control and Prevention. Estimates of future global tuberculosis morbidity and mortality. MMWR Morb Mortal Wkly Rep 1993;42:961-4.
4. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989;2:1502-4.
5. Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat. J Clin Invest 1995;95:2324-31.
6. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996;157:1271-8.
7. Whalen C, Horsburgh CR, Hom D, et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995;151:129-35.
8. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-72.
9. Collins FM. Mycobacteria as cofactor in AIDS. Res Microbiol 1992;143:369-72.
10. Lin Y, Zhang M, Hofman FM, Gong J, Barnes P. Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun 1996;64:1351-6.
11. Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993;61:3482-9.
12. Law K, Weiden M, Harkin T, et al. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996;153:799-804.
13. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
14. Ostrowski MA, Stanley SK, Justement JS, Gantt K, Goletti D, Fauci AS. Increased in vitro tetanus-induced production of HIV type 1 following in vivo immunization of HIV type 1-infected individuals with tetanus toxoid. AIDS Res Hum Retroviruses 1997;13:473-80.
15. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
16. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-6.
17. Warwick-Davies J, Lowrie DB, Cole PJ. Selective deactivation of human monocyte functions by TGF-β. J Immunol 1995;155:3186-93.
18. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
19. Weissman D, Daucher J, Barker T, et al. Cytokine regulation of HIV replication induced by dendritic cell-CD4-positive T cell interaction. AIDS Res Hum Retroviruses 1996;12:759-67.
20. Lederman MM, Georges D, Kusner DJ, Mudido P, Giam CZ, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:727-33.
21. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.
22. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727-33.
23. Jacobson J, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
24. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994;265:248-52.
25. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994;93:768-75.